Literature DB >> 22280945

Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke.

Xiaolan Yu1, Dongping Chen, Yang Zhang, Xiuli Wu, Zhixing Huang, Haitao Zhou, Yanding Zhang, Zhijian Zhang.   

Abstract

BACKGROUND: Stromal cell-derived factor-1 (SDF-1) and its cognate receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), are involved in the migration of stem cells. AIM: To test the hypothesis that mesenchymal stem cells (MSCs) with genetically modified CXCR4 can promote their own recruitment around the ischemic core.
METHODS: Lentiviral vectors were used to overexpress the CXCR4-eGFP fusion protein (CXCR4/eGFP) or eGFP only (eGFP) or to introduce siRNA targeting endogenous CXCR4 (siRNA/eGFP) in rat mesenchymal stem cells (rMSCs). Rats were injected with either the transduced rMSCs or PBS as a control via the femoral vein following a left middle cerebral artery occlusion (MCAO).
RESULTS: One week after MCAO, immunofluorescence staining revealed a significant increase in the number of eGFP-positive cells surrounding the infarct areas in the CXCR4-rMSC-treated group compared to the rMSC-treated control group. Conversely, there was a significant reduction in the number of eGFP-positive cells in the siRNA-rMSC-treated group. Moreover, there was an increase in the capillary vascular volume of the peri-infarct area, a reduction in the volume of the cerebral infarction and improved neurological function in the CXCR4-rMSC-treated group compared to those in the rMSC-, siRNA-rMSC- or PBS-treated groups.
CONCLUSION: CXCR4 overexpression in the rMSCs promoted their mobilization and enhanced neuroprotection in a rat cerebral ischemia model. This strategy may be a useful therapeutic approach for treating ischemic stroke.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22280945     DOI: 10.1016/j.jns.2012.01.001

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  36 in total

Review 1.  Update on therapeutic mechanism for bone marrow stromal cells in ischemic stroke.

Authors:  Huan Wan; Fangqin Li; Lei Zhu; Jing Wang; Zizhen Yang; Yujun Pan
Journal:  J Mol Neurosci       Date:  2013-09-19       Impact factor: 3.444

Review 2.  Cell based therapies for ischemic stroke: from basic science to bedside.

Authors:  Xinfeng Liu; Ruidong Ye; Tao Yan; Shan Ping Yu; Ling Wei; Gelin Xu; Xinying Fan; Yongjun Jiang; R Anne Stetler; George Liu; Jieli Chen
Journal:  Prog Neurobiol       Date:  2013-12-12       Impact factor: 11.685

3.  Elevated Serum Levels of CXC Chemokine Ligand-12 Are Associated with Unfavorable Functional Outcome and Mortality at 6-Month Follow-up in Chinese Patients with Acute Ischemic Stroke.

Authors:  Xuan Cheng; Ya-Jun Lian; Yun-Qing Ma; Nan-Chang Xie; Chuan-Jie Wu
Journal:  Mol Neurobiol       Date:  2016-01-16       Impact factor: 5.590

4.  Hyaluronic acid-laminin hydrogels increase neural stem cell transplant retention and migratory response to SDF-1α.

Authors:  C P Addington; S Dharmawaj; J M Heffernan; R W Sirianni; S E Stabenfeldt
Journal:  Matrix Biol       Date:  2016-09-17       Impact factor: 11.583

Review 5.  Intra-Arterial Delivery of Cell Therapies for Stroke.

Authors:  Raphael Guzman; Miroslaw Janowski; Piotr Walczak
Journal:  Stroke       Date:  2018-04-18       Impact factor: 7.914

Review 6.  Stem Cell-Based Immunomodulation After Stroke: Effects on Brain Repair Processes.

Authors:  Marieke C S Boshuizen; Gary K Steinberg
Journal:  Stroke       Date:  2018-05-03       Impact factor: 7.914

Review 7.  Bone marrow stromal cells as a therapeutic treatment for ischemic stroke.

Authors:  Zizhen Yang; Lei Zhu; Fangqin Li; Jing Wang; Huan Wan; Yujun Pan
Journal:  Neurosci Bull       Date:  2014-05-10       Impact factor: 5.203

Review 8.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

9.  Plasma CXCL12 levels as a predictor of future stroke.

Authors:  Robert C Schutt; Marie D Burdick; Robert M Strieter; Borna Mehrad; Ellen C Keeley
Journal:  Stroke       Date:  2012-10-04       Impact factor: 7.914

10.  Aqp1 enhances migration of bone marrow mesenchymal stem cells through regulation of FAK and β-catenin.

Authors:  Fanbiao Meng; Yunfeng Rui; Liangliang Xu; Chao Wan; Xiaohua Jiang; Gang Li
Journal:  Stem Cells Dev       Date:  2013-09-27       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.